Last updated on March 2019

Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction


Brief description of study

An open label, randomized controlled study in a Norwegian population with meibomian gland dysfunction. Patients will be randomized to one of two groups: THERAPEARL Eye Mask (Bausch & Lomb Inc., New York, USA) or Blephasteam (Spectrum Thea Pharmaceuticals LTD, Macclesfield, UK). All patients will receive Hylo-comod (URSAPHARM Arzneimittel GmbH, Saarbrcken, Germany).

Clinical Study Identifier: NCT03318874

Find a site near you

Start Over